Pro Farma AG
Recordati Switzerland is the Swiss affiliate of an international pharmaceutical group. The company markets proprietary and licensed prescription medicines across several therapeutic areas (notably urology, cardiology and psychiatry), provides medical information to healthcare professionals via a restricted portal, conducts research and development with a focus that includes rare diseases, and maintains pharmacovigilance and regulatory transparency processes.
Industries
Nr. of Employees
small (1-50)
Products
Prescription pharmaceutical portfolio (therapeutic categories)
Commercial portfolio of prescription medicines across cardiology, urology, psychiatry (including schizophrenia), gastroenterology and dermatology; includes proprietary and in-licensed products.
Prescription pharmaceutical portfolio (therapeutic categories)
Commercial portfolio of prescription medicines across cardiology, urology, psychiatry (including schizophrenia), gastroenterology and dermatology; includes proprietary and in-licensed products.
Services
Email and telephone contact channels for reporting adverse events and safety information for marketed medicines.
Gated online platform providing scientific information and specialist content to registered medical professionals.
Acquisition and commercialization of licensed pharmaceutical products and management of proprietary product distribution in local markets.
Supply and distribution of prescription-only medicines across multiple therapeutic areas to healthcare providers and patients.
Email and telephone contact channels for reporting adverse events and safety information for marketed medicines.
Gated online platform providing scientific information and specialist content to registered medical professionals.
Acquisition and commercialization of licensed pharmaceutical products and management of proprietary product distribution in local markets.
Supply and distribution of prescription-only medicines across multiple therapeutic areas to healthcare providers and patients.
Expertise Areas
- Pharmacovigilance
- Regulatory compliance and transparency reporting
- Commercialization and field sales
- Product licensing and partnerships
Key Technologies
- Pharmacovigilance reporting systems
- Gated medical information portals
- Regulatory disclosure and reporting processes
- Pharmaceutical manufacturing processes
News & Updates
Introduction (Oct 2018) of cariprazine, an atypical antipsychotic (partial dopamine agonist) for treatment of schizophrenia in adults.
Corporate renaming (Jan 2018) of the local affiliate formerly operating under a different name to Recordati AG based in Baar.
July 2017 acquisition of rights to a metoprolol product portfolio for European territories.
2016–2017 period included acquisition of the local affiliate by the group, repatriation of portfolio, and merger of local entities.
Introduction (Oct 2018) of cariprazine, an atypical antipsychotic (partial dopamine agonist) for treatment of schizophrenia in adults.
Corporate renaming (Jan 2018) of the local affiliate formerly operating under a different name to Recordati AG based in Baar.
July 2017 acquisition of rights to a metoprolol product portfolio for European territories.
2016–2017 period included acquisition of the local affiliate by the group, repatriation of portfolio, and merger of local entities.